UCB has agreed to divest its US generics drug unit Kremers Urban Pharmaceuticals to Advent International and Avista Capital Partners for US$1525 M. This deal will enable UCB to focus on its core areas of neurology and immunology and it intends to use the proceeds from the sale to reduce debt and invest in its R&D pipeline.